Nimmi Kapoor, MD, Breast and Thyroid Surgical Oncologist at Breastlink, discusses the benefits and safety of multigene panel testing in patients at risk for hereditary breast cancer.

Kapoor and her team conduced a study comparing multigene panel testing to the standard testing that has been traditionally done.

They looked at 966 patients, which were split into two groups, one which underwent standard testing and the other that underwent multigene panel testing. They found that almost identical rates of BRCA1 and 2 mutations, says Kapoor.

More interestingly, twice as many mutations were detected overall with the multigene panel testing than with the standard testing, says Kapoor. PALB2, CHEK2, and ATM, were identified with the multigene panel, common genes known to put women at risk for breast cancer,

Videos

Dr. Nimmi Kapoor on Multigene Panel Testing for Hereditary Breast Cancer

Nimmi S. Kapoor, MD, surgical oncologist, Breastlink Laguna Hills and Breastlink Orange, discusses the benefits and safety of multigene panel testing in patients who are at risk for hereditary breast cancer.

Kapoor discusses a study that compared the use of multigene panel testing with limited testing for 

 mutations in patients at risk for breast and ovarian cancer. The study enrolled 966 patients, 620 of which had limited testing done.

Results showed that multigene panel testing detects nearly identical rates for 

 as the standard limited testing, demonstrating the safety of multigene panel testing. However, multigene panel testing detected nearly double the amount of mutations in non-

 genes. The most commonly found mutations include 

Nimmi S. Kapoor, MD

Articles

Dr. Nimmi Kapoor on Multigene Panel Testing for Hereditary Breast Cancer

Dr. Kapoor on Multigene Panel Testing for Patients at Risk for Breast Cancer